Biomea Fusion (BMEA) Price & Analysis

Compare

864 Followers

BMEA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.29 - $13.07

Previous CloseN/A

Volume309.16K

Average Volume (3M)649.30K

Market Cap

$124.37M

Enterprise Value$23.96M

Total Cash (Recent Filing)$56.22M

Total Debt (Recent Filing)$7.05M

Price to Earnings (P/E)―

Beta1.28

Next Earnings

Nov 04, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding59,508,520

10 Day Avg. Volume722,128

30 Day Avg. Volume649,300

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.19

Enterprise Value/Revenue19.64

Enterprise Value/Gross Profit74.89

Enterprise Value/Ebitda-0.21

Forecast

1Y Price Target

$7.00

Price Target Upside234.93% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsNew trials are on track backed by favorable preclinical profiles, indicating positive potential for Biomea's pipeline.

Insulin ProductionThe durable effect on endogenous insulin production was indicated by significant improvements in C-peptide during the off-treatment period in the Phase 2 trial.

Metabolic BenefitsIcovamenib, in combination with semaglutide, demonstrated superior metabolic benefits in rodent models compared to semaglutide alone, highlighting its potential efficacy.

Type 2 Diabetes TreatmentThe COVALENT-111 trial exhibited clinically meaningful HbA1c reductions, supporting the potential of icovamenib as a novel therapy for T2D.

Bears Say

Financial PerformanceBiomea announced 2Q25 financial results, posting EPS of ($0.51) compared to our estimate of ($0.46), and in line with consensus.

Stock TargetTarget reduced to $4 on significant dilution.

Biomea Fusion News

Biomea Fusion reports inducment grants under Nasdaq listing rule

Biomea Fusion (BMEA) announced that on September 24, 2025, the compensation committee of Biomea’s board of directors granted...

1d ago

BMEA

Biomea Fusion announces presentation of preclinical data on icovamenib

Biomea Fusion (BMEA) announced the presentation of preclinical data from its investigational menin inhibitor icovamenib in combination with...

16d ago

BMEA

Biomea Fusion: Promising Clinical Pipeline and Strategic Focus Drive Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Biomea Fusion, with...

16d ago

BMEA

Five Below upgraded, Bill downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

AHL

Biomea Fusion initiated with a Buy at Jefferies

Jefferies initiated coverage of Biomea Fusion (BMEA) with a Buy rating and $5 price target Biomea is a...

1M ago

BMEA

Biomea Fusion: Promising Trials and Strategic Innovations Drive Buy Rating

Yigal Nochomovitz, an analyst from Citi, maintained the Buy rating on Biomea Fusion. The associated price target was...

2M ago

BMEA

Biomea Fusion price target lowered to $7 from $9 at Citi

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Biomea Fusion (BMEA) to $7 from $9 and...

2M ago

BMEA

Biomea Fusion price target lowered to $10 from $30 at Scotiabank

Scotiabank lowered the firm’s price target on Biomea Fusion (BMEA) to $10 from $30 and keeps an Outperform...

2M ago

BMEA

Promising Developments in Biomea Fusion’s Metabolic Programs Justify Buy Rating

Biomea Fusion, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

2M ago

BMEA

Biomea Fusion Reports Q2 2025 Financial Results

Biomea Fusion Inc ( ($BMEA) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

BMEA

Biomea Fusion price target lowered to $9 from $10 at Oppenheimer

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Biomea Fusion (BMEA) to $9 from $10 and...

2M ago

BMEA

Biomea Fusion files $300M mixed securities shelf

16:42 EDT Biomea Fusion (BMEA) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

BMEA

Biomea Fusion reports Q2 EPS (51c), consensus (51c)

“In the second quarter, we presented clinical and preclinical results with icovamenib that support its unique role as...

2M ago

BMEA

Biomea Fusion Announces Leadership Changes in Board

The latest announcement is out from Biomea Fusion ( ($BMEA) ). On July 22, 2025, Bihua Chen resigned...

2M ago

BMEA

BMEA FAQ

What was Biomea Fusion Inc’s price range in the past 12 months?

Biomea Fusion Inc lowest stock price was $1.29 and its highest was $13.07 in the past 12 months.

What is Biomea Fusion Inc’s market cap?

Biomea Fusion Inc’s market cap is $124.37M.

When is Biomea Fusion Inc’s upcoming earnings report date?

Biomea Fusion Inc’s upcoming earnings report date is Nov 04, 2025 which is in 33 days.

How were Biomea Fusion Inc’s earnings last quarter?

Biomea Fusion Inc released its earnings results on Aug 05, 2025. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.531 by $0.021.

Is Biomea Fusion Inc overvalued?

According to Wall Street analysts Biomea Fusion Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biomea Fusion Inc pay dividends?

Biomea Fusion Inc does not currently pay dividends.

What is Biomea Fusion Inc’s EPS estimate?

Biomea Fusion Inc’s EPS estimate is -0.29.

How many shares outstanding does Biomea Fusion Inc have?

Biomea Fusion Inc has 59,508,520 shares outstanding.

What happened to Biomea Fusion Inc’s price movement after its last earnings report?

Biomea Fusion Inc reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.531. Following the earnings report the stock price went up 0.633%.

Which hedge fund is a major shareholder of Biomea Fusion Inc?

Currently, no hedge funds are holding shares in BMEA

Biomea Fusion Stock Smart Score

Neutral

Fundamentals

Return on Equity

-170.53%

Trailing 12-Months

Asset Growth

-46.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Biomea Fusion Inc

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion (BMEA) Earnings & Revenues

Historic Earnings Reports

BMEA Stock 12 Month Forecast

Average Price Target

$7.00

▲(234.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.03,2.643076923076923,3.256153846153846,3.869230769230769,4.4823076923076925,5.095384615384615,5.708461538461538,6.321538461538461,6.934615384615384,7.547692307692307,8.16076923076923,8.773846153846154,9.386923076923077,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.03,2.4123076923076923,2.7946153846153843,3.1769230769230767,3.559230769230769,3.9415384615384617,4.323846153846153,4.706153846153846,5.088461538461539,5.470769230769231,5.853076923076923,6.235384615384616,6.617692307692307,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.03,2.1815384615384614,2.333076923076923,2.4846153846153847,2.636153846153846,2.787692307692308,2.939230769230769,3.0907692307692307,3.2423076923076923,3.393846153846154,3.5453846153846156,3.6969230769230768,3.848461538461539,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.75,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >